Ovarian Cancer Research Breakthrough in Auchenflower

Auchenflower researchers have mapped how immune cells interact with ovarian cancer tumours, a discovery that could guide more targeted treatments for patients.



Expanding Cancer Research in Auchenflower

Scientists at the Wesley Research Institute’s Queensland Spatial Biology Centre in Brisbane reported findings in iScience after investigating high-grade serous ovarian cancer, one of the deadliest forms of the disease. The centre, based in Auchenflower, had earlier in July 2025 published a head and neck cancer study in Nature Precision Oncology that showed how hundreds of protein and gene markers could be measured from a single biopsy to inform treatment.

Wesley Research Institute
Photo Credit: Wesley Research Institute

Mapping the Tumour Battlefield

The Auchenflower team analysed tumour samples from 49 patients using high-plex spatial proteomics to map the tumour microenvironment. Their work showed that survival chances improved when two specific immune cells, CD66+ cells and cytotoxic CD8 T-cells, were located close to tumour cells.

Why Immune Cells Matter

Researchers found that the positioning of these immune cells around the tumour boundary influenced whether the cells could recognise and attack cancer cells, which was associated with improved outcomes.

Advanced ovarian cancer
Photo Credit: Wesley Research Institute

Targeting Treatments Beyond Chemotherapy

Advanced ovarian cancer has a five-year survival rate of just 17 per cent. The findings suggest doctors could tailor therapies to target cancer cells more precisely while sparing healthy tissue. This approach may help reduce the broad side effects linked to chemotherapy by guiding more personalised treatment strategies.

Tumour Activity and Survival Links

The study also noted that tumour activity levels played a role, with survival outcomes varying depending on how metabolically active the tumours were and the presence of regulatory immune cells.

A Survivor’s Perspective

Survivor Merran Williams, 71, who carries the BRCA gene mutation, said her experience highlighted the importance of research that enables more targeted therapies. Having faced ovarian cancer three times and breast cancer once, she emphasised the need for treatments that are less harmful to the body.

Expanding Research Across the Globe



The Auchenflower researchers plan to expand their work to include hundreds of patients across Australia, the United States, Europe and Asia. The aim is to confirm immune-cell patterns linked to long-term survival and further refine treatment strategies.

Published 25-Sep-2025. Updated 6-October-2025.

Wesley Research Team in Auchenflower Leads Coeliac Drug Breakthrough

A small molecule drug being trialled in Auchenflower could soon change how coeliac disease is treated, by repairing the gut without suppressing the immune system.



Auchenflower Trial Offers New Hope for Locals Living With Coeliac Disease

A clinical trial underway in Auchenflower is bringing new hope to people living with coeliac disease, with early findings pointing to a treatment that may help repair the gut without relying solely on a gluten-free diet.

Photo Credit: Rawpixel

Led by Dr. James Daveson at Wesley Research Institute, the study tests IMU-856, a small molecule drug by U.S.-based Immunic Inc., as part of a broader trial across Australia and New Zealand. Results were recently published in The Lancet Gastroenterology & Hepatology.

A Different Approach to Treatment

Unlike current methods that require strict gluten avoidance, IMU-856 targets a protein called SIRT6, which plays a key role in maintaining the gut’s protective barrier. The drug supports gut wall repair and renewal without suppressing the immune system — a shift from traditional approaches.

The drug improved gut structure, eased symptoms, and boosted nutrient absorption in coeliac patients, with a favourable safety profile. Dr Daveson said it’s the first study to show IMU-856 may ease gluten-related damage in clinical conditions.

Community and Clinical Impact

Trial participants came from across Australia and New Zealand, with many attending appointments in Auchenflower. For locals managing coeliac disease, the study reflects an important step toward more flexible treatment options.

With results looking positive, the drug is expected to move into Phase 2 trials. Researchers are also exploring its potential for other gut disorders that currently have limited treatments.



What This Means for Auchenflower

The trial places Auchenflower at the heart of medical research that could reshape how coeliac disease is managed in Australia and beyond. As studies continue, residents and researchers alike are hopeful for what comes next.

Published 25-March-2025